Treatment-related toxicities were less likely with the lobaplatin-based regimen.
Cancer patients had a low rate of seropositivity after the first vaccine dose but not after the second dose.
A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.
Patient advocate Marlena Murphy provides a patient’s perspective on GRASP.
GRASP co-founder Julia Maués explains how the initiative came about and reveals plans for the future.
Researchers found associations between epigenetic age acceleration, inflammation, and fatigue in cancer patients.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Findings suggest a need for tailored treatment in oropharyngeal squamous cell carcinoma.
The combination significantly prolonged progression-free survival.
Adding toripalimab to chemotherapy improved progression-free survival.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
The median progression-free survival was not reached in either treatment group at a median follow-up of 15 months.
A study found no benefit to early palliative care interventions, suggesting a one-size-fits-all approach won’t work in head and neck cancer.
In an international, multicenter collaboration, experts modified the RECIST criteria for use as objective endpoints in clinical trials of retinoblastoma therapies.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
A team of investigators conducted a randomized controlled trial to assess outcomes following salvage endoscopic surgery vs radiation therapy in patients with resectable, locally recurrent nasopharyngeal cancer.
Investigators of the phase 3 KESTREL trial recruited 823 patients with previously untreated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Investigators tested the efficacy of reduced-dose radiation plus cisplatin in patients with good-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC).
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Population-based study demonstrated an association between patient-reported outcomes and ED visits/unplanned hospitalizations among patients with head and neck cancer.